이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
MacroGenics 관리
관리 기준 확인 3/4
MacroGenics' CEO는 Scott Koenig, Sep2001 에 임명되었습니다 의 임기는 22.75 년입니다. 총 연간 보상은 $ 3.71M, 19% 로 구성됩니다. 19% 급여 및 81% 보너스(회사 주식 및 옵션 포함). 는 $ 5.35M 가치에 해당하는 회사 주식의 2.07% 직접 소유합니다. 5.35M. 경영진과 이사회의 평균 재임 기간은 각각 7.4 년과 7 년입니다.
주요 정보
Scott Koenig
최고 경영자
US$3.7m
총 보상
CEO 급여 비율 | 19.0% |
CEO 임기 | 22.8yrs |
CEO 소유권 | 2.1% |
경영진 평균 재임 기간 | 7.4yrs |
이사회 평균 재임 기간 | 7yrs |
최근 관리 업데이트
Recent updates
MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
May 13MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
May 13MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Apr 05MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 28MacroGenics: Trying To Build A Better Everything
Feb 15There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
Jan 09Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price
May 17Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Mar 11Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
Jan 25Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Oct 25MacroGenics: No Near-Term Catalysts
Oct 11Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics
Sep 02MacroGenics Q2 2022 Earnings Preview
Aug 05Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky
Jul 25MacroGenics halts mid-stage head and neck cancer study after fatalities
Jul 11The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically
May 09We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Apr 12MacroGenics: Facing Considerable Headwinds From Unsatisfactory Trials
Feb 25Estimating The Intrinsic Value Of MacroGenics, Inc. (NASDAQ:MGNX)
Feb 18We're Not Very Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Nov 21MacroGenics: Revisiting Our Pipeline And Investment Analysis
Aug 10MacroGenics, Inc. (NASDAQ:MGNX) Analysts Are More Bearish Than They Used To Be
Aug 03MacroGenics collaborates with Zai Lab to develop bispecific antibodies in oncology
Jun 16CEO 보상 분석
날짜 | 총 보상 | 급여 | 회사 수익 |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$23m |
Dec 31 2023 | US$4m | US$705k | -US$9m |
Sep 30 2023 | n/a | n/a | US$50m |
Jun 30 2023 | n/a | n/a | US$7m |
Mar 31 2023 | n/a | n/a | -US$91m |
Dec 31 2022 | US$5m | US$673k | -US$120m |
Sep 30 2022 | n/a | n/a | -US$191m |
Jun 30 2022 | n/a | n/a | -US$219m |
Mar 31 2022 | n/a | n/a | -US$217m |
Dec 31 2021 | US$5m | US$651k | -US$202m |
Sep 30 2021 | n/a | n/a | -US$146m |
Jun 30 2021 | n/a | n/a | -US$129m |
Mar 31 2021 | n/a | n/a | -US$136m |
Dec 31 2020 | US$3m | US$656k | -US$130m |
Sep 30 2020 | n/a | n/a | -US$158m |
Jun 30 2020 | n/a | n/a | -US$167m |
Mar 31 2020 | n/a | n/a | -US$152m |
Dec 31 2019 | US$5m | US$590k | -US$152m |
Sep 30 2019 | n/a | n/a | -US$166m |
Jun 30 2019 | n/a | n/a | -US$155m |
Mar 31 2019 | n/a | n/a | -US$167m |
Dec 31 2018 | US$5m | US$599k | -US$171m |
Sep 30 2018 | n/a | n/a | -US$21m |
Jun 30 2018 | n/a | n/a | -US$34m |
Mar 31 2018 | n/a | n/a | -US$32m |
Dec 31 2017 | US$3m | US$554k | -US$20m |
보상 대 시장: Scott 의 총 보상 ($USD 3.71M )은 US 시장( $USD 1.62M ).
보상과 수익: Scott 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Scott Koenig (72 yo)
22.8yrs
테뉴어
US$3,705,825
보상
Dr. Scott Koenig, M.D., Ph D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig is Co-Founder of Macrogenics.He served as Senior Vice President of R...
리더십 팀
이름 | 위치 | 테뉴어 | 보상 | 소유권 |
---|---|---|---|---|
President | 22.8yrs | US$3.71m | 2.07% $ 5.3m | |
Senior VP | 16.1yrs | US$1.58m | 0.27% $ 697.8k | |
Senior VP of Clinical Development & Chief Medical Officer | 3.9yrs | US$1.75m | 0.016% $ 39.9k | |
Chief Operating Officer | 2.3yrs | US$1.92m | 0.062% $ 158.3k | |
Senior Vice President of Technical Operations | 1.6yrs | US$1.88m | 0.013% $ 33.9k | |
Senior VP of Research & Chief Scientific Officer | 7.8yrs | US$2.29m | 0.16% $ 410.6k | |
Senior VP | 7yrs | 데이터 없음 | 0% $ 0 | |
VP, Controller & Treasurer | 20.7yrs | 데이터 없음 | 0.0099% $ 25.3k |
7.4yrs
평균 재임 기간
61.5yo
평균 연령
경험이 풍부한 관리: MGNX 의 관리팀은 노련하고 경험 (평균 재직 기간 7.4 년)입니다.
이사회 구성원
이름 | 위치 | 테뉴어 | 보상 | 소유권 |
---|---|---|---|---|
President | 22.8yrs | US$3.71m | 2.07% $ 5.3m | |
Independent Director | 10.8yrs | US$160.75k | 0.0072% $ 18.3k | |
Independent Director | 3.3yrs | US$152.00k | 0.0072% $ 18.3k | |
Independent Director | 19.7yrs | US$147.63k | 0.060% $ 152.9k | |
Independent Director | 1.4yrs | US$318.32k | 0.0072% $ 18.3k | |
Independent Chairman of the Board | 2.1yrs | US$180.13k | 0.0072% $ 18.3k | |
Independent Director | 1.4yrs | US$335.41k | 0.0072% $ 18.3k | |
Independent Director | 7.4yrs | US$167.63k | 0.0072% $ 18.3k | |
Independent Director | 6.6yrs | US$167.21k | 0.0072% $ 18.3k | |
Independent Director | 7.4yrs | US$135.75k | 0.0072% $ 18.3k |
7.0yrs
평균 재임 기간
66yo
평균 연령
경험이 풍부한 이사회: MGNX 의 이사회는 경험(평균 재직 기간 7 년)으로 간주됩니다.